IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization ... - PR Newswire

September 12, 2024

IceCure Medical announces FDA Advisory Panel on ProSense® cryoablation for early-stage low risk breast cancer, expected to decide on marketing authorization by early 2025.

Highlighted Terms

FDA SEC IceCure Medical Ltd ProSense®IceCure Medical Ltd IceCure Medical Ltd FDA FDA's Medical Device Advisory Committee Panel SEC Advisory Panel Medical Device Advisory Committee Panel U.S. Food and Drug Administration ProSense®breast cancer SEC FDA breast cancer breast cancer

Related News

stocktitan.net

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ... - Stock Titan

IceCure Medical announces FDA Advisory Panel meeting on Nov 7, 2024, to discuss ProSense® cryoablation for early-stage low-risk breast cancer, with a decision expected by early 2025.

prnewswire.com

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization ... - PR Newswire

IceCure announces FDA Advisory Panel on ProSense® cryoablation for early-stage low risk breast cancer, expected to decide on marketing authorization by early 2025.

prnewswire.com

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization ... - PR Newswire

IceCure Medical announces FDA Advisory Panel on ProSense® cryoablation for early-stage low risk breast cancer, expected to decide on marketing authorization by early 2025.